科伦药业：子公司核心产品芦康沙妥珠单抗获批准第三项适应症

Core Viewpoint - The approval of sac-TMT, a targeted antibody-drug conjugate (ADC) by Kelun Pharmaceutical's subsidiary, marks a significant advancement in the treatment of advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR mutations after progression on EGFR tyrosine kinase inhibitors (TKIs) [1] Group 1 - Kelun Pharmaceutical's subsidiary, Kelun Biotech, received approval from the National Medical Products Administration (NMPA) for sac-TMT for a third indication [1] - Sac-TMT is the first and only ADC globally that has shown significant overall survival (OS) benefits compared to platinum-based doublet chemotherapy [1]